Approximately half of the more than 500,000 preterm births each year result from preterm
labor. Tocolytic therapy continues to be the focus of treatment of these women. Although a …

Preterm labor and delivery continues to be the most common problem in obstetrics today
and a major financial burden on the health care system. It has been estimated that this …

Although magnesium sulfate is widely used as a tocolytic agent in the hope of preventing
spontaneous preterm birth, there is a paucity of data from large well-designed randomized …

Abstract The US Food and Drug Administration issued a drug safety communication on
05/30/2013 recommending “against prolonged use of magnesium sulfate to stop preterm …

Objectives. We evaluated the efficacy of magnesium sulfate as a second‐line tocolysis for 48
hours. Materials and Methods. A multi‐institutional, simple 2‐arm randomized controlled trial …

Available evidence now suggests that magnesium sulfate administered to mothers prior to
early preterm delivery reduces the risk of cerebral palsy in surviving neonates. The …

OBJECTIVE: Magnesium sulfate is the most commonly used tocolytic agent for preterm
labor. A common clinical practice is to slowly discontinue the drug (wean) after successful …

Objective: To provide guidelines for the use of antenatal magnesium sulphate (MgSO4) for
fetal neuroprotection of the preterm infant. Options: Antenatal MgSO4 administration should …

One hundred fifty-six women with preterm labor between 24 and 34 weeks' gestation were
randomized to receive either intravenous magnesium sulfate or no tocolytic therapy …

Objective: This study was undertaken to compare a high-dose protocol for magnesium
sulfate tocolytic therapy with a low-dose regimen with respect to time needed to achieve …